Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Online Letters: Observations

Artificial Sweeteners Have No Effect on Gastric Emptying, Glucagon-Like Peptide-1, or Glycemia After Oral Glucose in Healthy Humans

  1. Tongzhi Wu, MBBS1,2,
  2. Michelle J. Bound, B MED RAD (NUC MED)1,2,
  3. Scott D. Standfield, BSC1,2,
  4. Max Bellon, DIP MED TECH AD NUC MED3,
  5. Richard L. Young, PHD1,2,4,
  6. Karen L. Jones, PHD1,2,
  7. Michael Horowitz, MBBS, PHD1,2 and
  8. Christopher K. Rayner, MBBS, PHD1,2⇑
  1. 1Discipline of Medicine, University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia
  2. 2Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia
  3. 3Department of Nuclear Medicine, Royal Adelaide Hospital, Adelaide, Australia
  4. 4Nerve-Gut Research Laboratory, Royal Adelaide Hospital, Adelaide, Australia
  1. Corresponding author: Christopher K. Rayner, chris.rayner{at}adelaide.edu.au.
Diabetes Care 2013 Dec; 36(12): e202-e203. https://doi.org/10.2337/dc13-0958
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Intestinal exposure to glucose stimulates the release of glucagon-like peptide-1 (GLP-1), slows subsequent gastric emptying, and reduces appetite. These responses are signaled, at least in part, by intestinal “sweet taste receptors” (STRs), including taste receptor type 1 members 2 and 3 (T1R2, T1R3), and their cellular signaling partners α-gustducin and transient receptor potential cation channel subfamily M member 5 (TRPM5) (1). A recent study by Brown et al. (2) in healthy humans reported that oral ingestion of “diet soda,” containing both sucralose (46 mg) and acesulfame potassium (AceK) (26 mg), augmented GLP-1 release by more than one-third after an oral glucose load given 10 min later compared with carbonated water, suggesting a potential synergy between artificial sweeteners and glucose in stimulating GLP-1 secretion. The design of that study was, however, suboptimal, as the diet soda contained a number of substances (including caramel color, gum acacia, natural flavors, citric acid, potassium benzoate, phosphoric acid, and potassium citrate) that were not controlled for. Therefore, we evaluated whether oral administration of sucralose and AceK in doses comparable with those used by Brown et al. (2) would augment the GLP-1 response to oral glucose and modulate gastric emptying or glycemia in healthy humans.

Ten healthy males (mean age 33.6 ± 5.9 years; BMI: 25.5 ± 1.0 kg/m2) were studied on four occasions each, separated by ≥3 days, in single-blinded randomized fashion. Informed consent and ethics approval were obtained. After an overnight fast, each subject consumed either 240 mL water alone or equivalently sweetened with 1) 52 mg sucralose, 2) 200 mg AceK, or 3) 46 mg sucralose plus 26 mg AceK (3). Ten minutes later, each drank 75 g of glucose, made up to 300 mL with water, and containing 150 mg 13C-acetate. Blood glucose (glucometer), plasma insulin (ELISA), total GLP-1 (radioimmunoassay), and gastric emptying (breath test) were evaluated over 240 min.

Blood glucose, plasma insulin, and total GLP-1 concentrations did not change after either water or sweetened drinks, prior to glucose ingestion, but all increased after oral glucose (P < 0.001 for each), without any difference between the 4 days (Fig. 1A–C). Neither the 13CO2:12CO2 ratio nor the half-emptying time (T50) differed between the 4 days (Fig. 1D and E).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Effects of ingestion of either water or artificial sweeteners (sucralose, AceK, or sucralose plus AceK) (at t = −10 min) on (A) blood glucose, (B) plasma insulin, (C) GLP-1, (D) 13CO2-to-12CO2 ratio, and (E) T50 in response to 75-g oral glucose (at t = 0 min) in healthy humans (n = 10). Data are means ± SEM. The area under the curves for blood glucose, plasma insulin, 13CO2-to-12CO2 ratio, and T50 did not differ between the 4 study days before and after 75-g oral glucose (one-factor repeated-measures ANOVA). There was a time effect (P < 0.001) but not a treatment effect or treatment × time interaction for blood glucose, plasma insulin, and 13CO2-to-12CO2 ratio (two-factor repeated-measures ANOVA with treatment and time as factors).

These observations differ from those of Brown et al. (2), although the doses of sucralose and AceK and the load and timing of the subsequent glucose drink were identical in our study. It is unclear whether other components of diet soda that were not controlled for by Brown et al. may have had the capacity to stimulate GLP-1 secretion. Our findings are, however, consistent with previous reports that sucralose or AceK alone has no effect on GLP-1 secretion, insulin, or blood glucose concentrations (3,4) and our observations that sucralose had no effect on GLP-1 secretion or the glycemic response to intraduodenal glucose in healthy humans (5). That the STR antagonist, lactisole, attenuates glucose-stimulated GLP-1 secretion suggests that activation of STRs is necessary, but not sufficient, to stimulate L-cell secretion (1). In conclusion, sucralose and AceK, either alone or in combination, have no acute effect on gastric emptying, GLP-1, or glycemic responses after oral glucose in healthy humans.

Acknowledgments

This work was funded by a grant awarded by the National Health and Medical Research Council (NHMRC) of Australia (no. 627139). K.L.J.’s salary is provided by an NHMRC Senior Clinical Career Development Award (NHMRC 627011).

No potential conflicts of interest relevant to this article were reported.

T.W. was involved in study design and coordination, subject recruitment, data collection and interpretation, statistical analysis, and the drafting of the manuscript; critically reviewed the manuscript; and approved the publication of the final version of the manuscript. M.J.B. assisted with data collection, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. S.D.S. performed insulin and GLP-1 assays, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. M.B. performed the gastric emptying analysis, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. R.L.Y., K.L.J., and M.H. were involved in the conception of the study and data interpretation, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. C.K.R. was involved in conception and design of the study and data interpretation, had overall responsibility for the study, critically reviewed the manuscript, and approved the publication of the final version of the manuscript. C.K.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Kylie Lange (Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide) for her expert statistical advice.

  • © 2013 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. Steinert RE,
    2. Gerspach AC,
    3. Gutmann H,
    4. Asarian L,
    5. Drewe J,
    6. Beglinger C
    . The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Clin Nutr 2011;30:524–532
    OpenUrlCrossRefPubMed
  2. ↵
    1. Brown RJ,
    2. Walter M,
    3. Rother KI
    . Ingestion of diet soda before a glucose load augments glucagon-like peptide-1 secretion. Diabetes Care 2009;32:2184–2186
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Steinert RE,
    2. Frey F,
    3. Töpfer A,
    4. Drewe J,
    5. Beglinger C
    . Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides. Br J Nutr 2011;105:1320–1328
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Ma J,
    2. Bellon M,
    3. Wishart JM,
    4. et al
    . Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009;296:G735–G739
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Ma J,
    2. Chang J,
    3. Checklin HL,
    4. et al
    . Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects. Br J Nutr 2010;104:803–806
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes Care: 36 (12)

In this Issue

December 2013, 36(12)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Artificial Sweeteners Have No Effect on Gastric Emptying, Glucagon-Like Peptide-1, or Glycemia After Oral Glucose in Healthy Humans
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Artificial Sweeteners Have No Effect on Gastric Emptying, Glucagon-Like Peptide-1, or Glycemia After Oral Glucose in Healthy Humans
Tongzhi Wu, Michelle J. Bound, Scott D. Standfield, Max Bellon, Richard L. Young, Karen L. Jones, Michael Horowitz, Christopher K. Rayner
Diabetes Care Dec 2013, 36 (12) e202-e203; DOI: 10.2337/dc13-0958

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Artificial Sweeteners Have No Effect on Gastric Emptying, Glucagon-Like Peptide-1, or Glycemia After Oral Glucose in Healthy Humans
Tongzhi Wu, Michelle J. Bound, Scott D. Standfield, Max Bellon, Richard L. Young, Karen L. Jones, Michael Horowitz, Christopher K. Rayner
Diabetes Care Dec 2013, 36 (12) e202-e203; DOI: 10.2337/dc13-0958
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Artifactual Hypoglycemia: An Old Term for a New Classification
  • Tyrosine Kinase Inhibitor Sunitinib Allows Insulin Independence in Long-standing Type 1 Diabetes
  • FGF23 in Type 2 Diabetic Patients: Relationship With Bone Metabolism and Vascular Disease
Show more Online Letters: Observations

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.